Literature DB >> 35089531

Paravertebral extramedullary hematopoiesis in a case of myelodysplastic syndrome with ring sideroblasts and an SF3B1 mutation.

Chie Asou1, Tomoya Maeda2, Maho Ishikawa2, Daisuke Okamura2, Mika Kohri2, Naoki Takahashi2, Kunihiro Tsukasaki2, Hirozo Sakaguchi3, Tsugumi Satoh4, Hidekazu Kayano5, Akira Matsuda2,6, Norio Asou2.   

Abstract

We present the case of a 56-year-old male patient with paravertebral extramedullary hematopoiesis (EMH) secondary to myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia. In a routine health checkup over 5 years prior, he presented with asymptomatic mild anemia and a posterior mediastinal mass. Pathological and cytomorphological findings of the resected paravertebral mass were similar to those of his bone marrow specimen, and included cellularity with erythroid hyperplasia, multilineage dysplastic changes, and the presence of ring sideroblasts. A concordant SF3B1 mutation was detected in both bone marrow and paravertebral mass samples, suggesting that the EMH cells were derived from the bone marrow.
© 2022. Japanese Society of Hematology.

Entities:  

Keywords:  Extramedullary hematopoiesis; Myelodysplastic syndromes; Paravertebral region; Ring sideroblasts; SF3B1 mutation

Year:  2022        PMID: 35089531     DOI: 10.1007/s12185-022-03291-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  2 in total

1.  Dysplastic extramedullary haematopoeisis with ringed sideroblasts mimicking adrenal adenoma.

Authors:  Carmen Martinez-Losada; Maria R Alhambra-Exposito; Rafael Sanchez-Sanchez; Javier Casaño; Carmen Tenorio-Jimenez; Joaquin Sanchez-Garcia
Journal:  Histopathology       Date:  2013-08-14       Impact factor: 5.087

2.  MR of thoracic cord compression caused by epidural extramedullary hematopoiesis in myelodysplastic syndrome.

Authors:  D A Dibbern; L A Loevner; A P Lieberman; K E Salhany; A Freese; P J Marcotte
Journal:  AJNR Am J Neuroradiol       Date:  1997-02       Impact factor: 3.825

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.